Clinical Trials in Osnabrück, Germany
12 recruiting
Showing 1–18 of 18 trials
Recruiting
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals700 enrolled108 locationsNCT06551519
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals800 enrolled111 locationsNCT05344469
Recruiting
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Breast Neoplasms
Novartis Pharmaceuticals3,250 enrolled267 locationsNCT06830720
Recruiting
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche842 enrolled74 locationsNCT06780150
Recruiting
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
Ovarian Cancer
AstraZeneca750 enrolled93 locationsNCT04830709
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled917 locationsNCT06677060
Recruiting
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Moderate to Severe Rheumatoid Arthritis
AbbVie678 enrolled53 locationsNCT06712628
Recruiting
SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
Parkinson Disease
Bial - Portela C S.A.90 enrolled12 locationsNCT07145190
Recruiting
Phase 3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Multiple Myeloma
University of Heidelberg Medical Center411 enrolled69 locationsNCT06216158
Recruiting
The AFteR Registry - Follow-up Study to Monitor the Efficacy and Safety of the Occlutech AFR in Heart Failure Patients
Heart Failure
Occlutech International AB150 enrolled36 locationsNCT04405583
Recruiting
Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Diabetes Mellitus, Type 1
Novo Nordisk A/S877 enrolled184 locationsNCT07076199
Recruiting
Phase 4
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
Diabetes Mellitus, Type 2
Novo Nordisk A/S586 enrolled75 locationsNCT07112339
Recruiting
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Parkinson's Disease (PD)
AbbVie450 enrolled68 locationsNCT06107426
Recruiting
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Chronic Lymphocytic Leukemia (CLL)
AbbVie500 enrolled70 locationsNCT03342144
Recruiting
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
Acute Lymphoblastic LeukemiaLeukemiaNon-Hodgkin's Lymphoma
Goethe University10,000 enrolled152 locationsNCT02872987
Recruiting
Phase 2Phase 3
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Hairy Cell Leukemia
University of Giessen210 enrolled76 locationsNCT02131753
Recruiting
Not Applicable
Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Universität Münster100 enrolled4 locationsNCT05920018
Recruiting
REDUCE LAP-HF III Corvia Protocol 1701
Heart Failure
Corvia Medical500 enrolled27 locationsNCT03191656